AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36189794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 33676197 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (1200 mg/2 weeks)
Number of subjects: 52
Study 33676197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 33676197 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 52
Study 35503768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling (altering first-line empiric therapy for Gram-negative bacteria every other 6-weeks)
Number of subjects: 1613
Study 35503768 — intervention group
Group type: COMPARATOR
Intervention: Mixing (changing antibiotic type every empiric antibiotic course)
Number of subjects: 1613
Study 35503768 — intervention group
Group type: COMPARATOR
Intervention: Mixing
Number of subjects: 1613
Study 35503768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling and Mixing
Number of subjects: 1613
Study 33847597 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention based on an HIV risk prediction tool
Number of subjects: 192
Study 33847597 — intervention group
Group type: COMPARATOR
Intervention: Control group (QR code only for resources on HIV health education)
Number of subjects: 192
Study 35716698 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Number of subjects: 0
Study 35716698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33154508 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon-Heated Tobacco Product (CHTP) 1.0 for 5 days
Number of subjects: 0
Study 33154508 — intervention group
Group type: COMPARATOR
Intervention: Cigarettes (control group)
Number of subjects: 0
Study 36253903 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, vegan diet and cooked soybeans (½ cup [86 g] daily)
Number of subjects: 84
Study 36253903 — intervention group
Group type: COMPARATOR
Intervention: Control group making no dietary changes
Number of subjects: 84
Study 32394874 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with liposomal amphotericin B (7.5 mg/kg, single dose) and short-course miltefosine (2.5 mg/kg/day for 14 days)
Number of subjects: 144
Study 32394874 — intervention group
Group type: COMPARATOR
Intervention: Miltefosine monotherapy (2.5 mg/kg/day for 28 days)
Number of subjects: 144
Study 32394874 — intervention group
Group type: COMPARATOR
Intervention: Miltefosine monotherapy
Number of subjects: 144
Study 32394874 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 144
Study 35939920 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐NeST plus treatment as‐usual (TAU)
Number of subjects: 30
Study 35939920 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 30
Study 33914314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg) + 50 mg dexketoprofen in 10 mL saline, administered 30 min before the procedure.
Number of subjects: 60
Study 33914314 — intervention group
Group type: COMPARATOR
Intervention: Control group received 50 mg dexketoprofen in 10 mL saline, administered 30 min before the procedure.
Number of subjects: 60
Study 32102723 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention group (IG)
Number of subjects: 61
Study 32102723 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 61
Study 35313167 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant pertuzumab (P) added to trastuzumab and chemotherapy
Number of subjects: 0
Study 35313167 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla) added to trastuzumab and chemotherapy
Number of subjects: 0
Study 33606918 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg
Number of subjects: 72
Study 33606918 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg
Number of subjects: 72
Study 33606918 — intervention group
Group type: COMPARATOR
Intervention: Sucrose alone
Number of subjects: 72
Study 32859662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multistep intervention (IA) incorporating electronic PRO assessment, case vignette, and expert-consented treatment recommendations
Number of subjects: 79
Study 32859662 — intervention group
Group type: COMPARATOR
Intervention: Control arm (CA)
Number of subjects: 79
Study 32859662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multistep intervention (IA)
Number of subjects: 79
Study 35329262 — intervention group
Group type: EXPERIMENTAL
Intervention: Kegel Exercise Pregnancy Training (KEPT) app
Number of subjects: 10
Study 33961667 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimune intervention group (n = 181) received care as usual (CAU) plus 12‐month access to Optimune immediately after randomization.
Number of subjects: 363
Study 33961667 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 182) received CAU and Optimune after a delay of 3 months.
Number of subjects: 363
Study 35551600 — intervention group
Group type: EXPERIMENTAL
Intervention: AD036 (atomoxetine 80 mg and oxybutynin 5 mg)
Number of subjects: 60
Study 35551600 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 80 mg alone
Number of subjects: 60
Study 35551600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 35567309 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic emotion regulation (ER) skills training
Number of subjects: 101
Study 35567309 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 101
Study 32335511 — intervention group
Group type: EXPERIMENTAL
Intervention: Speeding prevalence in Villahermosa
Number of subjects: 0
Study 32335511 — intervention group
Group type: EXPERIMENTAL
Intervention: Speeding prevalence in León
Number of subjects: 0
Study 32335511 — intervention group
Group type: EXPERIMENTAL
Intervention: Speeding prevalence in Cuernavaca
Number of subjects: 0
Study 32335511 — intervention group
Group type: EXPERIMENTAL
Intervention: Speeding prevalence in Guadalajara-Zapopan
Number of subjects: 0
Study 32335511 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall speeding prevalence
Number of subjects: 0
Study 34238537 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal 2-piece glass fiber-reinforced composite resin post (UNI)
Number of subjects: 39
Study 34238537 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin-custom glass fiber post (CTM)
Number of subjects: 39
Study 34238537 — intervention group
Group type: COMPARATOR
Intervention: Adapted glass fiber post with post space preparation of the same size
Number of subjects: 39
Study 33004790 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g whey protein drink (120 kcal)
Number of subjects: 20
Study 33004790 — intervention group
Group type: COMPARATOR
Intervention: Control (2 kcal)
Number of subjects: 20
Study 36346309 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 37
Study 36346309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 33474583 — intervention group
Group type: EXPERIMENTAL
Intervention: Being overweight at 2-10 years of age
Number of subjects: 2149
Study 33474583 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual growth measures
Number of subjects: 2149
Study 33474583 — intervention group
Group type: EXPERIMENTAL
Intervention: Being overweight (including obese) at 10 years
Number of subjects: 2149
Study 32346686 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol and calcium carbonate
Number of subjects: 120
Study 32346686 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (control)
Number of subjects: 120
Study 32346686 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ZOL with calcitriol and calcium carbonate
Number of subjects: 120
Study 32346686 — intervention group
Group type: COMPARATOR
Intervention: 5 mg ZOL with calcium carbonate (control)
Number of subjects: 120
Study 32346686 — intervention group
Group type: EXPERIMENTAL
Intervention: High VitD experimental group
Number of subjects: 120
Study 32346686 — intervention group
Group type: COMPARATOR
Intervention: Low VitD control group
Number of subjects: 120
Study 34363831 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (2 g immediate dose followed by 500 mg, twice a day, for 3 days) + Amoxicillin (1 g immediate dose followed by 500 mg, 4 times a day, for 7 days)
Number of subjects: 20
Study 34363831 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (1 g immediate dose followed by 500 mg, 4 times a day, for 7 days) + Placebo
Number of subjects: 20
Study 36416302 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed model for assessing treatment effect heterogeneity over exposure time
Number of subjects: 0
Study 36416302 — intervention group
Group type: EXPERIMENTAL
Intervention: Permutation test for the variance component of the heterogeneous treatment effect parameters
Number of subjects: 0
Study 35167358 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha-based yoga program delivered via telehealth
Number of subjects: 0
Study 36039009 — intervention group
Group type: EXPERIMENTAL
Intervention: solution-focussed education and counselling
Number of subjects: 44
Study 36039009 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 44
Study 34531878 — intervention group
Group type: EXPERIMENTAL
Intervention: Janus kinase (JAK) inhibitors for acute and chronic graft‐versus‐host disease (GVHD) and cytokine release syndrome (CRS)
Number of subjects: 0
Study 34531878 — intervention group
Group type: EXPERIMENTAL
Intervention: Janus kinase (JAK) inhibitors
Number of subjects: 0
Study 32101767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap and run procedure
Number of subjects: 15
Study 32101767 — intervention group
Group type: COMPARATOR
Intervention: Usual transfer
Number of subjects: 15
Study 34887529 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/10 mg OLZ/SAM for 21 days
Number of subjects: 60
Study 34887529 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg olanzapine for 21 days
Number of subjects: 60
Study 34887529 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 21 days
Number of subjects: 60
Study 33685474 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin soft gelatin capsule (5 mg twice a day for 7 days) along with standard treatment for COVID-19.
Number of subjects: 60
Study 33685474 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for COVID-19 based on the Iranian Ministry of Health and Medical Education’s protocol for 7 days.
Number of subjects: 60
Study 34898011 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring and feedback (SM+FB) with access to a customized smartphone application providing three daily feedback messages.
Number of subjects: 502
Study 34898011 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring without feedback (SM).
Number of subjects: 502
Study 33711941 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Hypertension Management (PHMA) intervention package including support for self-monitoring, supervised machine communications, daily education or reminder messages, weekly blood pressure notification, and quarterly signed feedback.
Number of subjects: 3352
Study 35768902 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg non-enteric coated aspirin for 1 week (NYU cohort)
Number of subjects: 150
Study 35768902 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg non-enteric coated aspirin for 4 weeks (Duke cohort)
Number of subjects: 150
Study 35768902 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg non-enteric coated aspirin for 4 weeks (Duke cohort)
Number of subjects: 150
Study 35768902 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 81 mg and 325 mg non-enteric coated aspirin (Duke cohort)
Number of subjects: 150
Study 33589771 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0
Study 33589771 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 35482631 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterfactual condition
Number of subjects: 73
Study 35482631 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 73
Study 33359367 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 106
Study 33359367 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 106
Study 32075605 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching television (TV)
Number of subjects: 480
Study 32075605 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing computer and video games
Number of subjects: 480
Study 32075605 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic media communication (EMC)
Number of subjects: 480
Study 32075605 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching TV
Number of subjects: 480
Study 32075605 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing computer and EMC
Number of subjects: 480
Study 35093561 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodic stimulation
Number of subjects: 9
Study 35093561 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetric biphasic stimulation (cathode-first)
Number of subjects: 9
Study 35093561 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetric biphasic stimulation (anode-first)
Number of subjects: 9
Study 35093561 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic pulse order (anode first)
Number of subjects: 9
Study 34330334 — intervention group
Group type: EXPERIMENTAL
Intervention: BREATHE Ethiopia
Number of subjects: 45
Study 34330334 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 45
Study 32569112 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention
Number of subjects: 75
Study 32569112 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 36006973 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Information Panel (NIP) with Added Sugar
Number of subjects: 2582
Study 36006973 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaspoons of Sugar
Number of subjects: 2582
Study 36006973 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning
Number of subjects: 2582
Study 36006973 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Star Rating (HSR) using Total Sugar
Number of subjects: 2582
Study 36006973 — intervention group
Group type: EXPERIMENTAL
Intervention: HSR with Added Sugar
Number of subjects: 2582
Study 36006973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar in the Ingredients List
Number of subjects: 2582
Study 36006973 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2582
Study 32000067 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided complete revascularization
Number of subjects: 1170
Study 32000067 — intervention group
Group type: COMPARATOR
Intervention: Angio-guided complete revascularization
Number of subjects: 1170
Study 35906990 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended pre-quit varenicline treatment
Number of subjects: 320
Study 35906990 — intervention group
Group type: COMPARATOR
Intervention: Standard pre-quit varenicline treatment
Number of subjects: 320
Study 35906990 — intervention group
Group type: EXPERIMENTAL
Intervention: Both positive and negative TOEs scores
Number of subjects: 320
Study 34817599 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal mental practice (MMMP) regimen
Number of subjects: 18
Study 34817599 — intervention group
Group type: COMPARATOR
Intervention: Repetitive task practice (RTP) only regimen
Number of subjects: 18
Study 32840621 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based self-care (MBSC) training
Number of subjects: 82
Study 32840621 — intervention group
Group type: COMPARATOR
Intervention: Life-as-usual control
Number of subjects: 82
Study 36111174 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronically-delivered EMPOWER (EMPOWER-ED) protocol
Number of subjects: 0
Study 36111174 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control)
Number of subjects: 0
Study 33407580 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive device (Wrex by Jaeco)
Number of subjects: 36
Study 33407580 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-active device (Armon Ayura)
Number of subjects: 36
Study 32770314 — intervention group
Group type: EXPERIMENTAL
Intervention: Total leukocytes count
Number of subjects: 0
Study 32770314 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil count
Number of subjects: 0
Study 34649978 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivopixant 150 mg
Number of subjects: 31
Study 34649978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 34976108 — intervention group
Group type: EXPERIMENTAL
Intervention: AI + personalized sports management service
Number of subjects: 150
Study 34976108 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 34119469 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy withdrawal
Number of subjects: 51
Study 34119469 — intervention group
Group type: COMPARATOR
Intervention: Control (continued therapy)
Number of subjects: 51
Study 32037861 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (stationary bicycle training, 4 weeks, 5 times per week, 30-minute sessions, intensity 65%-80% of maximal heart rate)
Number of subjects: 20
Study 32037861 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 20
Study 35623995 — intervention group
Group type: EXPERIMENTAL
Intervention: Spotify patient-preferred music selection (Group I, n=37)
Number of subjects: 77
Study 35623995 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimalist hypnotic music with guided relaxation breathing (MHMGRB) (Group II, n=40)
Number of subjects: 77
Study 35623995 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group I and Group II
Number of subjects: 77
Study 33876885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous neuromodulation (PNM) intervention on the sciatic nerve
Number of subjects: 30
Study 32679434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Load (GL) diet
Number of subjects: 23
Study 32679434 — intervention group
Group type: COMPARATOR
Intervention: High Glycemic Load (GL) diet
Number of subjects: 23
Study 32679434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GL diet during rice meal challenge
Number of subjects: 23
Study 32679434 — intervention group
Group type: COMPARATOR
Intervention: High GL diet during rice meal challenge
Number of subjects: 23
Study 32679434 — intervention group
Group type: EXPERIMENTAL
Intervention: CGM measurements
Number of subjects: 23
Study 35427446 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-lexical training (N = 24)
Number of subjects: 62
Study 35427446 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical training (N = 24)
Number of subjects: 62
Study 35427446 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in noise (N = 12)
Number of subjects: 62
Study 35427446 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in silence (N = 12)
Number of subjects: 62
Study 35427446 — intervention group
Group type: COMPARATOR
Intervention: Untrained control group (N = 14)
Number of subjects: 62
Study 34769831 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT‐R
Number of subjects: 20
Study 34769831 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFT
Number of subjects: 20
Study 32751430 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized instructions (EG)
Number of subjects: 0
Study 32751430 — intervention group
Group type: COMPARATOR
Intervention: Intuitive or non-standardized instructions (CG)
Number of subjects: 0
Study 33165214 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal repair
Number of subjects: 183
Study 33165214 — intervention group
Group type: COMPARATOR
Intervention: Postnatal repair
Number of subjects: 183
Study 34919239 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) combined with plyometric exercise
Number of subjects: 32
Study 32723722 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality mindful exposure therapy (VR-MET) sessions, daily surveys, and online peer-to-peer support for 21 days.
Number of subjects: 120
Study 33870752 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral strategies for PA
Number of subjects: 436
Study 34291584 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/aspart (IDegAsp)
Number of subjects: 87
Study 34291584 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin (control)
Number of subjects: 87
Study 34460294 — intervention group
Group type: EXPERIMENTAL
Intervention: GSLC curriculum (Evolution: DNA and the Unity of Life)
Number of subjects: 2269
Study 34460294 — intervention group
Group type: COMPARATOR
Intervention: Typical NGSS-friendly units without molecular genetics
Number of subjects: 2269
Study 34120134 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer Tool (OT+)
Number of subjects: 89
Study 34120134 — intervention group
Group type: COMPARATOR
Intervention: No Observer Tool (OT-)
Number of subjects: 89
Study 34034279 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemocoagulase Bothrops Atrox
Number of subjects: 120
Study 34034279 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 120
Study 34818588 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (motivational interviewing sessions, 2 weeks of nicotine replacement therapy)
Number of subjects: 252
Study 34818588 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care, referral to Quitline)
Number of subjects: 252
Study 34818588 — intervention group
Group type: COMPARATOR
Intervention: Intervention and Control
Number of subjects: 252
Study 33719579 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg twice daily for 7 days)
Number of subjects: 69
Study 33719579 — intervention group
Group type: COMPARATOR
Intervention: Placebo (7 days of treatment)
Number of subjects: 69
Study 33719579 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation program (12 weeks)
Number of subjects: 69
Study 33719579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 69
Study 32682994 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sugar and carbohydrate education (LSC) + blinded CGM
Number of subjects: 60